{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,5]],"date-time":"2026-06-05T02:00:41Z","timestamp":1780624841840,"version":"3.54.1"},"reference-count":58,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,4,21]],"date-time":"2026-04-21T00:00:00Z","timestamp":1776729600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,6,5]],"date-time":"2026-06-05T00:00:00Z","timestamp":1780617600000},"content-version":"vor","delay-in-days":45,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"a statutory subsidy from the Ministry of Health as part of the Department of Oncology, Wroclaw Medical University's research grant","award":["SUBZ.C280.26.041"],"award-info":[{"award-number":["SUBZ.C280.26.041"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"DOI":"10.1186\/s12885-026-16017-y","type":"journal-article","created":{"date-parts":[[2026,4,21]],"date-time":"2026-04-21T10:23:52Z","timestamp":1776767032000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Prevalence of recurrent and non-recurrent BRCA1 and BRCA2 pathogenic variants in Polish breast cancer patients: insights from a regional genetic testing cohort from Lower Silesia"],"prefix":"10.1186","volume":"26","author":[{"given":"Rafal","family":"Matkowski","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mariola","family":"Abrahamowska","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dagmara","family":"Michalowska","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Agnieszka","family":"Chrusciel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jolanta","family":"Szelachowska","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dorota","family":"Blomka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paulina","family":"Lawicka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ewelina","family":"Czykalko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aleksandra","family":"Pietron","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcin","family":"Ekiert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Doraczynska-Kowalik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriela","family":"Janus-Szymanska","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Piotr","family":"Kasprzak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bartlomiej","family":"Szynglarewicz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Izabela","family":"Laczmanska","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,4,21]]},"reference":[{"key":"16017_CR1","doi-asserted-by":"publisher","first-page":"584","DOI":"10.1200\/JCO.23.02225","volume":"42","author":"I Bedrosian","year":"2024","unstructured":"Bedrosian I, Somerfield MR, Achatz MI, Boughey JC, Curigliano G, Friedman S, et al. Germline Testing in Patients with Breast Cancer: ASCO-Society of Surgical Oncology Guideline. J Clin Oncol Lippincott Williams Wilkins. 2024;42:584\u2013604. https:\/\/doi.org\/10.1200\/JCO.23.02225. Cited 5 May 2025.","journal-title":"J Clin Oncol Lippincott Williams Wilkins"},{"key":"16017_CR2","doi-asserted-by":"publisher","unstructured":"Doraczy\u0144ska-Kowalik A, Micha\u0142owska D, Matkowski RA, Czyka\u0142ko E, Blomka D, Semeniuk M, et al. Detection of BRCA1\/2 pathogenic variants in patients with breast and\/or ovarian cancer and their families. Analysis of 3,458 cases from Lower Silesia (Poland) according to the diagnostic algorithm of the National Cancer Control Programme. Front Genet. 2022;13. https:\/\/doi.org\/10.3389\/fgene.2022.941375.","DOI":"10.3389\/fgene.2022.941375"},{"key":"16017_CR3","doi-asserted-by":"publisher","unstructured":"Menezes MCS, Raheem F, Mina L, Ernst B, Batalini F. PARP Inhibitors for Breast Cancer: Germline BRCA1\/2 and Beyond. Cancers (Basel). MDPI; 2022. https:\/\/doi.org\/10.3390\/cancers14174332.","DOI":"10.3390\/cancers14174332"},{"key":"16017_CR4","doi-asserted-by":"publisher","unstructured":"Godet I, Gilkes M. D. BRCA1 and BRCA2 mutations and treatment strategies for breast cancer. Integr Cancer Sci Ther. Volume 4. Open Access Text Pvt, Ltd.; 2017. https:\/\/doi.org\/10.15761\/ICST.1000228.\u00a0Cited 24 Jan 2025.","DOI":"10.15761\/ICST.1000228"},{"key":"16017_CR5","doi-asserted-by":"publisher","unstructured":"McAlarnen L, Stearns K, Uyar D. Challenges of Genomic Testing for Hereditary Breast and Ovarian Cancers. Appl Clin Genet. Dove Press; 2021;14:1. https:\/\/doi.org\/10.2147\/TACG.S245021. Cited 25 Jan 2022.","DOI":"10.2147\/TACG.S245021"},{"key":"16017_CR6","doi-asserted-by":"publisher","unstructured":"McDevitt T, Durkie M, Arnold N, Burghel GJ, Butler S, Claes KBM, et al. EMQN best practice guidelines for genetic testing in hereditary breast and ovarian cancer. European Journal of Human Genetics. Springer Nature; 2024. pp. 479\u201388. https:\/\/doi.org\/10.1038\/s41431-023-01507-5.","DOI":"10.1038\/s41431-023-01507-5"},{"key":"16017_CR7","doi-asserted-by":"publisher","unstructured":"El Ansari FZ, Jouali F, Marchoudi N, Bennani MM, Ghailani NN, Barakat A et al. Screening of BRCA1\/2 genes mutations and copy number variations in patients with high risk for hereditary breast and ovarian cancer syndrome (HBOC). BMC Cancer. 2020;20. https:\/\/doi.org\/10.1186\/s12885-020-07250-0.\u00a0Cited 21 Jan 2022.","DOI":"10.1186\/s12885-020-07250-0"},{"key":"16017_CR8","doi-asserted-by":"publisher","unstructured":"Suszynska M, Klonowska K, Jasinska AJ, Kozlowski P. Large-scale meta-analysis of mutations identified in panels of breast\/ovarian cancer-related genes - Providing evidence of cancer predisposition genes. Gynecol Oncol. Gynecol Oncol; 2019;153:452\u201362. https:\/\/doi.org\/10.1016\/J.YGYNO.2019.01.027.\u00a0Cited 27 Jan 2025.","DOI":"10.1016\/J.YGYNO.2019.01.027"},{"key":"16017_CR9","doi-asserted-by":"publisher","first-page":"683","DOI":"10.1002\/ijc.20162","volume":"110","author":"B G\u00f3rski","year":"2004","unstructured":"G\u00f3rski B, Jakubowska A, Huzarski T, Byrski T, Gronwald J, Grzybowska E, et al. A high proportion of founder BRCA1 mutations in Polish breast cancer families. Int J Cancer. 2004;110:683\u20136. https:\/\/doi.org\/10.1002\/ijc.20162.","journal-title":"Int J Cancer"},{"key":"16017_CR10","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1007\/S13167-010-0037-Y","volume":"1","author":"R Janavi\u010dius","year":"2010","unstructured":"Janavi\u010dius R. Founder BRCA1\/2 mutations in the Europe: implications for hereditary breast-ovarian cancer prevention and control. EPMA J EPMA J. 2010;1:397\u2013412. https:\/\/doi.org\/10.1007\/S13167-010-0037-Y. Cited 24 Jan 2025.","journal-title":"EPMA J EPMA J"},{"key":"16017_CR11","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1007\/S10549-022-06782-2","volume":"197","author":"A Kechin","year":"2023","unstructured":"Kechin A, Boyarskikh U, Barinov A, Tanas A, Kazakova S, Zhevlova A, et al. A spectrum of BRCA1 and BRCA2 germline deleterious variants in ovarian cancer in Russia. Breast Cancer Res Treat Breast Cancer Res Treat. 2023;197:387\u201395. https:\/\/doi.org\/10.1007\/S10549-022-06782-2. Cited 24 Jan 2025.","journal-title":"Breast Cancer Res Treat Breast Cancer Res Treat"},{"key":"16017_CR12","doi-asserted-by":"publisher","DOI":"10.1016\/J.PRP.2023.154475","author":"K Jan\u00edkov\u00e1","year":"2023","unstructured":"Jan\u00edkov\u00e1 K, V\u00e1\u0148ov\u00e1 B, Grend\u00e1r M, Samec M, Loderer D, Ka\u0161ubov\u00e1 I, et al. Small-scale variants and large deletions in BRCA1\/2 genes in Slovak high-grade serous ovarian cancer. Pathol Res Pract Pathol Res Pract. 2023;246. https:\/\/doi.org\/10.1016\/J.PRP.2023.154475. Cited 24 Jan 2025.","journal-title":"Pathol Res Pract Pathol Res Pract"},{"key":"16017_CR13","doi-asserted-by":"publisher","unstructured":"Sk\u00f3rniak J, Rabalski L, Szynglarewicz B, Do\u0142\u0119ga-Kozierowski B, Kasprzak P, Zi\u0119tek M, et al. Breast Cancer Stage Among Ukrainian Refugees in Poland. JAMA Netw Open. American Medical Association; 2025;8:e256215 https:\/\/doi.org\/10.1001\/JAMANETWORKOPEN.2025.6215. Cited 5 May 2025.","DOI":"10.1001\/JAMANETWORKOPEN.2025.6215"},{"key":"16017_CR14","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1038\/gim.2015.30","volume":"17","author":"S Richards","year":"2015","unstructured":"Richards S, Aziz N, Bale S, Bick D, Das S, Gastier-Foster J, et al. Standards and guidelines for the interpretation of sequence variants: A joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology. Genetics in Medicine. Nat Publishing Group. 2015;17:405\u201324. https:\/\/doi.org\/10.1038\/gim.2015.30.","journal-title":"Nat Publishing Group"},{"key":"16017_CR15","doi-asserted-by":"publisher","first-page":"1453","DOI":"10.1016\/S0140-6736(07)61602-X","volume":"370","author":"E von Elm","year":"2007","unstructured":"von Elm E, Altman DG, Egger M, Pocock SJ, G\u00f8tzsche PC, Vandenbroucke JP. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. Lancet Elsevier. 2007;370:1453\u20137. https:\/\/doi.org\/10.1016\/S0140-6736(07)61602-X. Cited 2025 Oct 23];.","journal-title":"Lancet Elsevier"},{"key":"16017_CR16","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1158\/2159-8290.CD-12-0095","volume":"2","author":"E Cerami","year":"2012","unstructured":"Cerami E, Gao J, Dogrusoz U, Gross BE, Sumer SO, Aksoy BA, et al. The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data. Cancer Discov Cancer Discov. 2012;2:401\u20134. https:\/\/doi.org\/10.1158\/2159-8290.CD-12-0095. Cited 30 Mar 2026.","journal-title":"Cancer Discov Cancer Discov"},{"key":"16017_CR17","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1002\/CNCR.29041","volume":"121","author":"J Mersch","year":"2015","unstructured":"Mersch J, Jackson MA, Park M, Nebgen D, Peterson SK, Singletary C, et al. Cancers associated with BRCA1 and BRCA2 mutations other than breast and ovarian. Cancer Cancer. 2015;121:269\u201375. https:\/\/doi.org\/10.1002\/CNCR.29041. Cited 12 Feb 2025.","journal-title":"Cancer Cancer"},{"key":"16017_CR18","doi-asserted-by":"publisher","unstructured":"Gradishar WJ, Moran MS, Abraham J, Abramson V, Aft R, Agnese D et al. NCCN Guidelines\u00ae Insights: Breast Cancer, Version 5.2025. J Natl Compr Canc Netw. J Natl Compr Canc Netw; 2025;23:426\u201336. https:\/\/doi.org\/10.6004\/JNCCN.2025.0053. Cited 30 Mar 2026.","DOI":"10.6004\/JNCCN.2025.0053"},{"key":"16017_CR19","unstructured":"Dwyer M. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines \u00ae) Genetic\/Familial High-Risk Assessment: Breast, Ovarian, Pancreatic, and Prostate. 2025. https:\/\/www.nccn.org\/home\/member-. Accessed 7 Mar 2025.\u00a0. Cited 7 Mar 2025."},{"key":"16017_CR20","doi-asserted-by":"publisher","unstructured":"DeFrancesco MS, Waldman RN, Pearlstone MM, Karanik D, Bernhisel R, Logan J, et al. Hereditary cancer risk assessment and genetic testing in the community-practice setting. Obstetrics and Gynecology. Volume 132. Lippincott Williams and Wilkins; 2018. pp. 1121\u20139. https:\/\/doi.org\/10.1097\/AOG.0000000000002916. Cited 13 Mar 2025.","DOI":"10.1097\/AOG.0000000000002916"},{"key":"16017_CR21","doi-asserted-by":"publisher","first-page":"1721","DOI":"10.1002\/cncr.30498","volume":"123","author":"SS Buys","year":"2017","unstructured":"Buys SS, Sandbach JF, Gammon A, Patel G, Kidd J, Brown KL, et al. A study of over 35,000 women with breast cancer tested with a 25-gene panel of hereditary cancer genes. Cancer John Wiley Sons Inc. 2017;123:1721\u201330. https:\/\/doi.org\/10.1002\/cncr.30498.","journal-title":"Cancer John Wiley Sons Inc"},{"key":"16017_CR22","doi-asserted-by":"publisher","unstructured":"Garutti M, Foffano L, Mazzeo R, Michelotti A, Da Ros L, Viel A et al. Hereditary Cancer Syndromes: A Comprehensive Review with a Visual Tool. Genes (Basel). Genes (Basel); 2023;14. https:\/\/doi.org\/10.3390\/GENES14051025. Cited 13 Mar 2025.","DOI":"10.3390\/GENES14051025"},{"key":"16017_CR23","doi-asserted-by":"publisher","unstructured":"Dubsky P, Jackisch C, Im SA, Hunt KK, Li CF, Unger S, et al. BRCA genetic testing and counseling in breast cancer: how do we meet our patients\u2019 needs? npj Breast Cancer 2024 10:1. Volume 10. Nature Publishing Group; 2024. pp. 1\u201312. https:\/\/doi.org\/10.1038\/s41523-024-00686-8. Cited 13 Mar 2025.","DOI":"10.1038\/s41523-024-00686-8"},{"key":"16017_CR24","unstructured":"ESMO Clinical Practice Guideline. Risk Reduction and Screening of Cancer in Hereditary Breast-Ovarian Cancer syndromes | ESMO. https:\/\/www.esmo.org\/guidelines\/esmo-clinical-practice-guideline-risk-reduction-and-screening-of-cancer-in-hereditary-breast-ovarian-cancer-syndromes. Accessed 30 Mar 2026.\u00a0Cited 30 Mar 2026."},{"key":"16017_CR25","doi-asserted-by":"publisher","first-page":"1475","DOI":"10.1016\/J.ANNONC.2021.09.019","volume":"32","author":"A Gennari","year":"2021","unstructured":"Gennari A, Andr\u00e9 F, Barrios CH, Cort\u00e9s J, de Azambuja E, DeMichele A, et al. ESMO Clinical Practice Guideline for the diagnosis, staging and treatment of patients with metastatic breast cancer \u2606. Annals Oncol Elsevier Ltd. 2021;32:1475\u201395. https:\/\/doi.org\/10.1016\/J.ANNONC.2021.09.019.","journal-title":"Annals Oncol Elsevier Ltd"},{"key":"16017_CR26","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1002\/HUMU.23406","volume":"39","author":"TR Rebbeck","year":"2018","unstructured":"Rebbeck TR, Friebel TM, Friedman E, Hamann U, Huo D, Kwong A, et al. Mutational spectrum in a worldwide study of 29,700 families with BRCA1 or BRCA2 mutations. Hum Mutat John Wiley Sons Inc. 2018;39:593\u2013620. https:\/\/doi.org\/10.1002\/HUMU.23406.","journal-title":"Hum Mutat John Wiley Sons Inc"},{"key":"16017_CR27","doi-asserted-by":"publisher","DOI":"10.1001\/JAMA.2025.16372","author":"G Idumah","year":"2025","unstructured":"Idumah G, Newell D, Hadrys M, Ribaudo I, Ni Y, Arbesman J. Pathogenic Germline Variants in Cancer Susceptibility Genes. JAMA JAMA. 2025. https:\/\/doi.org\/10.1001\/JAMA.2025.16372. Cited 5 Nov 2025.","journal-title":"JAMA JAMA"},{"key":"16017_CR28","doi-asserted-by":"publisher","unstructured":"O\u2019Brien KM, Keil AP, Taylor JA, Weinberg CR, Polley EC, Yadav S et al. Pathogenic Variants, Family History, and Cumulative Risk of Breast Cancer in US Women. JAMA Oncol. JAMA Oncol; 2025; https:\/\/doi.org\/10.1001\/JAMAONCOL.2025.3875. Cited 5 Nov 2025.","DOI":"10.1001\/JAMAONCOL.2025.3875"},{"key":"16017_CR29","doi-asserted-by":"publisher","first-page":"1417","DOI":"10.1016\/S1470-2045(25)00400-0","volume":"26","author":"D Black","year":"2025","unstructured":"Black D, Davies HR, Koh GCC, Chmelova L, Cubric M, Chalivelaki Chan G, et al. Clinical potential of whole-genome data linked to mortality statistics in patients with breast cancer in the UK: a retrospective analysis. Lancet Oncol Elsevier. 2025;26:1417\u201331. https:\/\/doi.org\/10.1016\/S1470-2045(25)00400-0.","journal-title":"Lancet Oncol Elsevier"},{"key":"16017_CR30","doi-asserted-by":"publisher","unstructured":"Wojcik P, Jasiowka M, Strycharz E, Sobol M, Hodorowicz-Zaniewska D, Skotnicki P, et al. Recurrent mutations of BRCA1, BRCA2 and PALB2 in the population of breast and ovarian cancer patients in Southern Poland. Hered Cancer Clin Pract. Volume 14. BioMed Central Ltd.; 2016. p. 5. https:\/\/doi.org\/10.1186\/s13053-016-0046-5. Cited 4 Mar 2025.","DOI":"10.1186\/s13053-016-0046-5"},{"key":"16017_CR31","doi-asserted-by":"publisher","unstructured":"\u0141ukomska A, Menkiszak J, Gronwald J, Tomiczek-Szwiec J, Szwiec M, Jasi\u00f3wka M et al. Recurrent Mutations in BRCA1, BRCA2, RAD51C, PALB2 and CHEK2 in Polish Patients with Ovarian Cancer. Cancers (Basel). Cancers (Basel); 2021 Cited;13:1\u201311. https:\/\/doi.org\/10.3390\/CANCERS13040849. Cited 4 Mar 2025.","DOI":"10.3390\/CANCERS13040849"},{"key":"16017_CR32","doi-asserted-by":"publisher","unstructured":"Kluz T, Jasiewicz A, Marczyk E, Jach R, Jakubowska A, Lubi\u0144ski J et al. Frequency of BRCA1 and BRCA2 causative founder variants in ovarian cancer patients in South-East Poland. Hered Cancer Clin Pract. BioMed Central Ltd.; 2018;16:1\u20134. https:\/\/doi.org\/10.1186\/S13053-018-0089-X\/TABLES\/2.\u00a0Cited 12 Feb 2025.","DOI":"10.1186\/S13053-018-0089-X\/TABLES\/2"},{"key":"16017_CR33","doi-asserted-by":"publisher","unstructured":"Kowalik A, Sio\u0142ek M, Kopczy\u0144ski J, Krawiec K, Kalisz J, Zi\u0119ba S et al. BRCA1 founder mutations and beyond in the Polish population: A single-institution BRCA1\/2 next-generation sequencing study. 2018. https:\/\/doi.org\/10.1371\/journal.pone.0201086.\u00a0Cited 12 Feb 2025.","DOI":"10.1371\/journal.pone.0201086"},{"key":"16017_CR34","doi-asserted-by":"publisher","first-page":"1963","DOI":"10.1086\/302922","volume":"66","author":"B G\u00f3rski","year":"2000","unstructured":"G\u00f3rski B, Byrski T, Huzarski T, Jakubowska A, Menkiszak J, Gronwald J, et al. Founder mutations in the BRCA1 gene in Polish families with breast-ovarian cancer. Am J Hum Genet Am J Hum Genet. 2000;66:1963\u20138. https:\/\/doi.org\/10.1086\/302922. Cited 4 Mar 2025.","journal-title":"Am J Hum Genet Am J Hum Genet"},{"key":"16017_CR35","doi-asserted-by":"publisher","unstructured":"Kiser D, Elhanan G, Bolze A, Neveux I, Schlauch KA, Metcalf WJ, et al. Screening Familial Risk for Hereditary Breast and Ovarian Cancer. JAMA Netw Open. American Medical Association; 2024;7: e2435901\u20132435901. https:\/\/doi.org\/10.1001\/JAMANETWORKOPEN.2024.35901.\u00a0Cited 18 Feb 2025.","DOI":"10.1001\/JAMANETWORKOPEN.2024.35901"},{"key":"16017_CR36","doi-asserted-by":"publisher","DOI":"10.1007\/S10549-025-07643-4","author":"M Potrony","year":"2025","unstructured":"Potrony M, Morales-Romero B, Moreno L, Pastor B, Grau E, Badenas C, et al. Considerations for hereditary breast and ovarian cancer syndrome molecular diagnosis: experience from the clinical practice. Breast Cancer Res Treat Breast Cancer Res Treat. 2025. https:\/\/doi.org\/10.1007\/S10549-025-07643-4. Cited 7 Mar 2025.","journal-title":"Breast Cancer Res Treat Breast Cancer Res Treat"},{"key":"16017_CR37","doi-asserted-by":"publisher","DOI":"10.3389\/FGENE.2022.941375","author":"A Doraczynska-Kowalik","year":"2022","unstructured":"Doraczynska-Kowalik A, Michalowska D, Matkowski R, Czykalko E, Blomka D, Semeniuk M, et al. Detection of BRCA1\/2 pathogenic variants in patients with breast and\/or ovarian cancer and their families. Analysis of 3,458 cases from Lower Silesia (Poland) according to the diagnostic algorithm of the National Cancer Control Programme. Front Genet Front Genet. 2022;13. https:\/\/doi.org\/10.3389\/FGENE.2022.941375. Cited 7 Mar 2025.","journal-title":"Front Genet Front Genet"},{"key":"16017_CR38","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1200\/JCO.18.01631","volume":"37","author":"PD Beitsch","year":"2019","unstructured":"Beitsch PD, Whitworth PW, Hughes K, Patel R, Rosen B, Compagnoni G, et al. Underdiagnosis of Hereditary Breast Cancer: Are Genetic Testing Guidelines a Tool or an Obstacle? J Clin Oncol J Clin Oncol. 2019;37:453\u201360. https:\/\/doi.org\/10.1200\/JCO.18.01631. Cited 7 Mar 2025.","journal-title":"J Clin Oncol J Clin Oncol"},{"key":"16017_CR39","doi-asserted-by":"publisher","DOI":"10.1001\/JAMANETWORKOPEN.2024.31427","author":"Z Rezoug","year":"2024","unstructured":"Rezoug Z, Totten SP, Szlachtycz D, Atayan A, Mohler K, Albert S, et al. Universal Genetic Testing for Newly Diagnosed Invasive Breast Cancer. JAMA Netw Open JAMA Netw Open. 2024. https:\/\/doi.org\/10.1001\/JAMANETWORKOPEN.2024.31427. Cited 7 Mar 2025.\u00a0","journal-title":"JAMA Netw Open JAMA"},{"key":"16017_CR40","doi-asserted-by":"publisher","first-page":"380","DOI":"10.1136\/JMEDGENET-2019-106403","volume":"57","author":"J Lerner-Ellis","year":"2020","unstructured":"Lerner-Ellis J, Lerner-Ellis J, Lerner-Ellis J, Sopik V, Wong A, L\u00e1zaro C, et al. Retesting of women who are negative for a BRCA1 and BRCA2 mutation using a 20-gene panel. J Med Genet J Med Genet. 2020;57:380\u20134. https:\/\/doi.org\/10.1136\/JMEDGENET-2019-106403. Cited 7 Mar 2026 .","journal-title":"J Med Genet J Med Genet"},{"key":"16017_CR41","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1056\/NEJMOA1913948","volume":"384","author":"LDSCJA A G-N","year":"2021","unstructured":"A G-N LDSCJA, C CL. Breast Cancer Risk Genes - Association Analysis in More than 113,000 Women. N Engl J Med N Engl J Med. 2021;384:428\u201339. https:\/\/doi.org\/10.1056\/NEJMOA1913948. Cited 27 Mar 2026 .","journal-title":"N Engl J Med N Engl J Med"},{"key":"16017_CR42","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1056\/NEJMOA2005936","volume":"384","author":"C Hu","year":"2021","unstructured":"Hu C, Hart SN, Gnanaolivu R, Huang H, Lee KY, Na J, et al. A Population-Based Study of Genes Previously Implicated in Breast Cancer. N Engl J Med. N Engl J Med. 2021;384:440\u201351. https:\/\/doi.org\/10.1056\/NEJMOA2005936. Cited 27 Mar 2026 .","journal-title":"N Engl J Med"},{"key":"16017_CR43","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1016\/J.HUMPATH.2018.10.005","volume":"84","author":"IMH S\u00f8nderstrup","year":"2019","unstructured":"S\u00f8nderstrup IMH, Jensen MBR, Ejlertsen B, Eriksen JO, Gerdes AM, Kruse TA, et al. Subtypes in BRCA-mutated breast cancer. Hum Pathol W B Saunders. 2019;84:192\u2013201. https:\/\/doi.org\/10.1016\/J.HUMPATH.2018.10.005.","journal-title":"Hum Pathol W B Saunders"},{"key":"16017_CR44","doi-asserted-by":"publisher","DOI":"10.1038\/S41598-020-63759-1","author":"S Talhouet","year":"2020","unstructured":"Talhouet S, De, Peron J, Vuilleumier A, Friedlaender A, Viassolo V, Ayme A, et al. Clinical outcome of breast cancer in carriers of BRCA1 and BRCA2 mutations according to molecular subtypes. Sci Rep Sci Rep. 2020;10. https:\/\/doi.org\/10.1038\/S41598-020-63759-1. Cited 30 May 2026.","journal-title":"Sci Rep Sci Rep"},{"key":"16017_CR45","doi-asserted-by":"publisher","first-page":"87151","DOI":"10.18632\/oncotarget.19895","volume":"8","author":"Y Xie","year":"2017","unstructured":"Xie Y, Gou Q, Wang Q, Zhong X, Zheng H. The role of BRCA status on prognosis in patients with triple-negative breast cancer. Oncotarget Impact Journals LLC. 2017;8:87151\u201362. https:\/\/doi.org\/10.18632\/oncotarget.19895.","journal-title":"Oncotarget Impact Journals LLC"},{"key":"16017_CR46","doi-asserted-by":"publisher","unstructured":"Park WK, Chung SY, Jung YJ, Ha C, Kim JW, Nam SJ, et al. Long-term oncologic outcomes of unselected triple-negative breast cancer patients according to BRCA1\/2 mutations. npj Precision Oncology 2024 8:1. Nature Publishing Group; 2024;8:96 . https:\/\/doi.org\/10.1038\/s41698-024-00559-0. Cited 30 May 2026.","DOI":"10.1038\/s41698-024-00559-0"},{"key":"16017_CR47","doi-asserted-by":"publisher","first-page":"383866","DOI":"10.3389\/FPHAR.2018.00909\/TEXT","volume":"9","author":"H Chen","year":"2018","unstructured":"Chen H, Wu J, Zhang Z, Tang Y, Li X, Liu S, et al. Association between BRCA status and triple-negative breast cancer: A meta-analysis. Front Pharmacol Front Media S A. 2018;9:383866. https:\/\/doi.org\/10.3389\/FPHAR.2018.00909\/TEXT. Cited 30 May 2026.","journal-title":"Front Pharmacol Front Media S A"},{"key":"16017_CR48","doi-asserted-by":"publisher","unstructured":"Adamovich AI, Diabate M, Banerjee T, Nagy G, Smith N, Duncan K et al. The functional impact of BRCA1 BRCT domain variants using multiplexed DNA double-strand break repair assays. Am J Hum Genet. Cell Press; 2022;109:618. https:\/\/doi.org\/10.1016\/J.AJHG.2022.01.019. Cited 31 May 2026.","DOI":"10.1016\/J.AJHG.2022.01.019"},{"key":"16017_CR49","doi-asserted-by":"publisher","first-page":"993","DOI":"10.1016\/J.AJHG.2024.12.011","volume":"112","author":"L Ramadane-Morchadi","year":"2025","unstructured":"Ramadane-Morchadi L, Rotenberg N, Esteban-S\u00e1nchez A, Fortuno C, G\u00f3mez-Sanz A, Varga MJ, et al. ACMG\/AMP interpretation of BRCA1 missense variants: Structure-informed scores add evidence strength granularity to the PP3\/BP4 computational evidence. Am J Hum Genet Cell Press. 2025;112:993. https:\/\/doi.org\/10.1016\/J.AJHG.2024.12.011. Cited 31 May 2026.","journal-title":"Am J Hum Genet Cell Press"},{"key":"16017_CR50","doi-asserted-by":"publisher","first-page":"38","DOI":"10.25122\/JML-2024-0213","volume":"18","author":"FD Alday-Monta\u00f1ez","year":"2025","unstructured":"Alday-Monta\u00f1ez FD, Dickens-Terrazas D, Mejia-Carmona GE, Robles-Escajeda E, Kirken RA, Bencomo-Alvarez AE, et al. Pathogenic variants in BRCA1 and BRCA2 genes associated with female breast and ovarian cancer in the Mexican population. J Med Life J Med Life. 2025;18:38\u201347. https:\/\/doi.org\/10.25122\/JML-2024-0213. Cited 31 May 2026.","journal-title":"J Med Life J Med Life"},{"key":"16017_CR51","doi-asserted-by":"publisher","unstructured":"Szczerba E, Kami\u0144ska K, Mierzwa T, Misiek M, Kowalewski J, Lewandowska MA. BRCA1\/2 Mutation Detection in the Tumor Tissue from Selected Polish Patients with Breast Cancer Using Next Generation Sequencing. Genes (Basel). Genes (Basel); 2021;12. https:\/\/doi.org\/10.3390\/GENES12040519. Cited 7 May 2025.","DOI":"10.3390\/GENES12040519"},{"key":"16017_CR52","doi-asserted-by":"publisher","first-page":"3993","DOI":"10.1093\/HMG\/DDS222","volume":"21","author":"K Biswas","year":"2012","unstructured":"Biswas K, Das R, Eggington JM, Qiao H, North SL, Stauffer S, et al. Functional evaluation of BRCA2 variants mapping to the PALB2-binding and C-terminal DNA-binding domains using a mouse ES cell-based assay. Hum Mol Genet Hum Mol Genet. 2012;21:3993\u20134006. https:\/\/doi.org\/10.1093\/HMG\/DDS222. Cited 31 May 2026.","journal-title":"Hum Mol Genet Hum Mol Genet"},{"key":"16017_CR53","doi-asserted-by":"publisher","unstructured":"Huang H, Hu C, Na J, Hart SN, Gnanaolivu RD, Abozaid M et al. Functional evaluation and clinical classification of BRCA2 variants. Nature. 2025 638:8050. Nature Publishing Group; 2025;638:528\u201337. https:\/\/doi.org\/10.1038\/s41586-024-08388-8. Cited 31 May 2026.","DOI":"10.1038\/s41586-024-08388-8"},{"key":"16017_CR54","doi-asserted-by":"publisher","unstructured":"Han SA, Kim SW, Kang E, Park SK, Ahn SH, Lee MH et al. The prevalence of BRCA mutations among familial breast cancer patients in Korea: Results of the Korean Hereditary Breast Cancer study. Fam Cancer. Fam Cancer; 2013;12:75\u201381. https:\/\/doi.org\/10.1007\/S10689-012-9578-7. Cited 5 May 2025.","DOI":"10.1007\/S10689-012-9578-7"},{"key":"16017_CR55","doi-asserted-by":"publisher","unstructured":"Armstrong N, Ryder S, Forbes C, Ross J, Quek RGW. A systematic review of the international prevalence of BRCA mutation in breast cancer. Clin Epidemiol. Volume 11. Dove Medical Press Ltd; 2019. pp. 543\u201361. https:\/\/doi.org\/10.2147\/CLEP.S206949.\u00a0Cited 5 May 2025.","DOI":"10.2147\/CLEP.S206949"},{"key":"16017_CR56","doi-asserted-by":"publisher","DOI":"10.3390\/IJMS20143442","author":"P Concolino","year":"2019","unstructured":"Concolino P, Gelli G, Rizza R, Costella A, Scambia G, Capoluongo E. BRCA1 and BRCA2 Testing through Next Generation Sequencing in a Small Cohort of Italian Breast\/Ovarian Cancer Patients: Novel Pathogenic and Unknown Clinical Significance Variants. Int J Mol Sci. Multidisciplinary Digital Publishing Institute (MDPI); 2019;20. https:\/\/doi.org\/10.3390\/IJMS20143442. Cited 21 Jan 2022.","journal-title":"Int J Mol Sci"},{"key":"16017_CR57","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1186\/S13073-023-01191-6\/FIGURES\/3","volume":"15","author":"JM Ravel","year":"2023","unstructured":"Ravel JM, Renaud M, Muller J, Becker A, Renard \u00c9, Remen T, et al. Clinical utility of periodic reinterpretation of CNVs of uncertain significance: an 8-year retrospective study. Genome Med BioMed Central Ltd. 2023;15:39\u2013. https:\/\/doi.org\/10.1186\/S13073-023-01191-6\/FIGURES\/3. Cited 2 Apr 2026.","journal-title":"Genome Med BioMed"},{"key":"16017_CR58","doi-asserted-by":"publisher","unstructured":"Rogo\u017ca-Janiszewska E, Mali\u0144ska K, Cybulski C, Jakubowska A, Gronwald J, Huzarski T et al. Prevalence of Recurrent Mutations Predisposing to Breast Cancer in Early-Onset Breast Cancer Patients from Poland. Cancers (Basel). Cancers (Basel); 2020;12:1\u201310. https:\/\/doi.org\/10.3390\/CANCERS12082321.\u00a0Cited 12 Nov 2025.","DOI":"10.3390\/CANCERS12082321"}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12885-026-16017-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-026-16017-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-026-16017-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,5]],"date-time":"2026-06-05T01:21:26Z","timestamp":1780622486000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12885-026-16017-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,21]]},"references-count":58,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["16017"],"URL":"https:\/\/doi.org\/10.1186\/s12885-026-16017-y","relation":{},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,21]]},"assertion":[{"value":"16 February 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 April 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 April 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was conducted in accordance with the Declaration of Helsinki. All tested patients provided written informed consent for genetic testing and for the use of results for research purposes.The Wroclaw Medical University Ethics Committee evaluated and authorised the experiment (No. 233\/2025).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval and consent to participate"}},{"value":"The authors consent to the publication of the submitted work and confirm that all necessary permissions have been obtained.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"714"}}